Eli Lilly to Acquire Ajax Therapeutics in Deal Worth Up to $2.3 Billion
Eli Lilly will acquire Ajax Therapeutics for up to $2.3 billion, strengthening its pipeline in blood cancer treatments.
#Oncology
Explore MarketSpeaker's latest reporting, research, and expert analysis tagged with "oncology", collected in one continuously updated archive.
Related Posts